Prof. B. Griffin
University College Cork, School of Pharmacy, Ireland

Position
Lecturer in Pharmaceutics at the School of Pharmacy at University College Cork

Background
Currently a Lecturer in Pharmaceutics at the School of Pharmacy as University College Cork. Having completed his BSc. Pharm. degree at the School of Pharmacy in Trinity College Dublin (TCD), he proceeded to a PhD. in the Pharmaceutics at TCD.  After working in pharmaceutical industry for a number of years (at Élan and Servier), he returned to academia in 2005.  He is also Course Director of the MSc in Pharmaceutical Technology and Quality Systems, an on line masters course designed to train graduates working in the pharmaceutical industry to become a Qualified Person (QP).

Prof. Griffin research interests focus on the development of optimised and targeted drug delivery systems.  This includes lipid based formulations for enhancing oral bioavailability of poorly soluble drug compounds; design of nanoparticulate based drug delivery systems; targeted drug delivery to the brain and to the intestinal lymphatics.  He continues to interact closely with the pharmaceutical industry and has a number of research collaborations with industrial partners.

Role in PEARRL
Main Supervisor ESR 1 and ESR 9, Co-Supervisor ESR 5 and ESR 14

Key Publications
  • 'In vitro bidirectional permeability studies identify pharmacokinetic limitations of NKCC1 inhibitor bumetanide' Donovan, M.D., Schellekens, H., Boylan, G.B., Cryan, J.F.,Griffin, B.T. (2015) 'In vitro bidirectional permeability studies identify pharmacokinetic limitations of NKCC1 inhibitor bumetanide'. European Journal of Pharmacology,
  • 'Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: in vitro, in vivo and in silico assessments' O'Shea, J.P.; Faisal, W; Ruane-O’Hora, T; Devine, K.J.; Kostewicz, E.S.; O'Driscoll, C.M.; Griffin, B.T. (2015) 'Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: in vitro, in vivo and in silico assessments'. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 96 :207-216
  • 'Treating Disorders of the Neonatal Central Nervous System: Pharmacokinetic and Pharmacodynamic Considerations with a Focus on Anti-epileptics-' Donovan, M.D., Boylan, G.B., Murray, D.M., Cryan, J.F , Griffin, B.T., (2015) 'Treating Disorders of the Neonatal Central Nervous System: Pharmacokinetic and Pharmacodynamic Considerations with a Focus on Anti-epileptics-'. British Journal of Clinical Pharmacology,
  • 'Enhanced Colonic Delivery of Ciclosporin A Self-Emulsifying Drug Delivery System encapsulated in Coated Minispheres' Keohane, K; Rosa, M.; Coulter, I.S, Griffin, B.T. (2015) 'Enhanced Colonic Delivery of Ciclosporin A Self-Emulsifying Drug Delivery System encapsulated in Coated Minispheres'. Drug Development and Industrial Pharmacy, Early online
  • 'Exploring the Impact of Drug Properties on the Extent of Intestinal Lymphatic Transport-In Vitro and In Vivo Studies'Lawless, E., Griffin, B.T., O’Mahony, A., O’Driscoll, C.M. (2015) 'Exploring the Impact of Drug Properties on the Extent of Intestinal Lymphatic Transport-In Vitro and In Vivo Studies'. Pharmaceutical Research, :1-13
  • 'The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: an integrated in vivo microdialysis study in the rat'Maria D. Donovan, Fionn E. O'Brien, Geraldine B. Boylan, John F. Cryan, Brendan T. Griffin (2014) 'The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: an integrated in vivo microdialysis study in the rat'. Journal of Pharmacy and Pharmacology,
  • 'Silicon microfluidic flow focusing devices for the production of size-controlled PLGA based drug loaded microparticles'Keohane, Kieran and Brennan, Des and Galvin, Paul and Griffin, Brendan T (2014) 'Silicon microfluidic flow focusing devices for the production of size-controlled PLGA based drug loaded microparticles'. International Journal of Pharmaceutics, 467 (1):60-69